Illumina launches TruPath Genome, setting a new standard in genomic insight

TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology" SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.

PRNewsWire • 7 hours ago

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaS eq X systems , advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 billion reads (35B).

PRNewsWire • Feb 23, 2026

Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 18, 2026

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference TD Cowen 46th Annual Health Care Conference 2026 on March 3, 2026 The fireside chat is scheduled for 12:10pm PT (3:10pm ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.

PRNewsWire • Feb 17, 2026

Invesco International Growth Fund Q4 2025 Portfolio Update

Invesco International Growth Fund underperformed most in industrials, consumer discretionary and communication services, all due to stock selection. We initiated five positions during the quarter, four of which we can discuss now. We eliminated seven positions. Relative to its index, the fund outperformed most in financials, health care and energy, all due to stock selection.

Seeking Alpha • Feb 16, 2026

Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips

ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.

Zacks Investment Research • Feb 12, 2026

Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 12, 2026

Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks Investment Research • Feb 9, 2026

Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 6, 2026

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis) Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis) GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7% GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35 Fiscal year 2025 results: Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basis Ex-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basis GAAP operating margin of 18.6% and non-GAAP operating margin of 23.1% GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84 Fiscal year 2026 guidance: For fiscal year 2026, we expect: Total company revenue of $4.5 billion to $4.6 billion, representing growth of 4% - 6% on a reported basis, including a 1.5% - 2.0% benefit from the recently closed SomaLogic acquisition Ex-China Organic revenue growth of 2% - 4%, which excludes currency and acquisition impacts Non-GAAP operating margin in the range of 23.3% - 23.5%, including a negative impact of 100bps from the SomaLogic acquisition Non-GAAP diluted EPS in the range of $5.05 - $5.20, including $0.18 in dilution from the SomaLogic acquisition SAN DIEGO, Feb. 5, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the fourth quarter and fiscal year 2025. "The Illumina team delivered a strong finish to 2025, marking a return to growth through disciplined execution against our strategy," said Jacob Thaysen, Chief Executive Officer of Illumina.

PRNewsWire • Feb 5, 2026